SEK 0.03
-0.00 (-8.82%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ATORX.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer PatientsNCT04888312Incidence of Dose Limiting Toxicities (DLTs) (Part 1: Phase 1b Dose escalation)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: CD40 agonist mitazalimab in combination with chemotherapy | Metastatic Pancreatic Ductal Adenocarcinoma | 94 | 2026-06-01 | 2025-10-08 |
| Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017NCT04144842Safety and tolerability: Adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 5.0Open-label · Treatment | Phase 1 | Completed | Biological: ATOR-1017 | Solid Tumor, Neoplasms | 27 | 2023-03-29actual | 2023-04-24 |
| Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015NCT03782467Safety and tolerability: Adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0Open-label · Treatment | Phase 1 | Completed | Biological: ATOR-1015 | Solid Tumor, Neoplasms | 33 | 2021-03-03actual | 2022-08-18 |
| ADC-1013 First-in-Human StudyNCT02379741Safety and tolerability of increasing doses of ADC-1013, assessed by medical review of AE reports and vital signs measurements (blood pressure, pulse rate, body temperature), physical examinations, ECGs and clinical laboratory tests.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: ADC-1013 | Neoplasms, Solid Tumors | 24 | 2017-03-08actual | 2017-03-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19